5 Amino 1MQ (10mg)
$68.00
RESEARCH USE ONLY
Available on backorder
Description
To confirm authenticity, see the Registered Certificate of Analysis on the THIRD PARTY testing lab website: https://coas.freedomdiagnosticstesting.com/Disc2608210094.pdf
Click here to view and download the THIRD PARTY CERTIFICATE OF ANALYSIS
5-Amino-1MQ is an experimental small-molecule compound that has attracted attention for its ability to inhibit nicotinamide N-methyltransferase (NNMT). Research into NNMT inhibition has focused heavily on body composition, fat metabolism, glucose handling, insulin sensitivity, and metabolic health.
One important distinction: 5-Amino-1MQ is not a peptide. It is a small-molecule NNMT inhibitor, but it is frequently grouped with peptides and other research compounds on peptide-focused websites.
Product Information
NNMT is an enzyme involved in the metabolism of nicotinamide and methyl donors. Researchers have linked increased NNMT activity with metabolic dysfunction, obesity, and insulin resistance.
5-Amino-1MQ, also referred to in research as 5A1MQ, has been investigated as an NNMT inhibitor. Recent mouse research found that daily 5A1MQ treatment limited weight and fat-mass gain, improved glucose tolerance and insulin sensitivity, and reduced markers of fatty liver disease.
How Does 5-Amino-1MQ Work?
5-Amino-1MQ works by inhibiting NNMT, an enzyme that converts nicotinamide into 1-methylnicotinamide. Reducing NNMT activity can alter cellular NAD+ and methylation-related metabolism, which is the basis for its metabolic research interest.
5-Amino-1MQ Benefits
Supports Fat-Metabolism Research
Animal studies have produced some of the strongest interest in 5-Amino-1MQ. In diet-induced obese mice, 5A1MQ treatment dose-dependently limited increases in body weight and fat mass, supporting further investigation of NNMT inhibition as a metabolic strategy.
Improves Glucose and Insulin-Sensitivity Markers in Animal Models
Recent research found that 5A1MQ improved oral glucose tolerance and insulin sensitivity while reducing hyperinsulinemia in obese mice. These findings position NNMT inhibition as an interesting area of metabolic research, although the results cannot be directly assumed to occur in humans.
Research Into Fatty Liver
5A1MQ-treated obese mice showed reductions in hepatic steatosis, liver triglycerides, liver weight, and macrophage infiltration. This has made NNMT inhibition particularly interesting in research examining the connection between obesity, liver metabolism, and insulin resistance.
Supports NAD+-Related Metabolic Research
NNMT inhibition can alter intracellular metabolic pathways involving NAD+ and S-adenosylmethionine (SAM). Earlier research into methylquinolinium NNMT inhibitors demonstrated increased intracellular NAD+ alongside reduced lipogenesis in adipocytes, helping explain why this pathway has attracted metabolic-research interest.
